ACTIVE_NOT_RECRUITING

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Conditions

Heart Failure Ischemic Heart Failure NYHA Class II-III Implantable Cardioverter Defibrillator (ICD)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of receiving the study drug. Participants who are enrolled to receive the study drug will be admitted to the General Clinical Research Center (GCRC) for 5 days for oral thyroid hormone treatment and monitoring. They will have 4 additional follow-up visits over the next year. Participants who are not enrolled to receive the study drug will not be admitted but will have similar follow-up visits in the outpatient setting. Participants who do not receive the drug in Phase I will have the opportunity to enroll in Phase II of the study where everyone will receive the thyroid hormone treatment. If this study finds that patients have improved heart function after treatment with thyroid hormone without unacceptable side effects, this could result in a new treatment for patients with heart failure.

Official Title

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Quick Facts

Study Start:2022-12-02

Study Completion:2026-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05384847

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Aged 18-80 years, male or female; * Confirmed diagnosis of ischemic HF with left ventricular ejection fraction (LVEF) ≤ 40% (measured by echocardiography within 1 month of Screening); * Stable symptoms; NYHA class II-III without recent admission (1 month) for acute decompensation; * Receiving guideline-based standard HF therapies at the maximum tolerated doses for \>1 month. Patients on other beta-blockers will be switched to metoprolol succinate at equivalent doses for 3 weeks. * Presence of ICD for \>1 month or implantable cardiac resynchronization therapy defibrillator (CRT-D) for \>3 months * Understand and sign the informed consent form.	* LVEF \> 40%; * Unremitting atrial fibrillation during the screening period or clinically significant ventricular tachycardia (on ICD interrogation); * Non-ischemic HF including hypertrophic cardiomyopathy, peripartum or chemotherapy-induced cardiomyopathy, other non-ischemic cardiomyopathies, constrictive pericarditis, significant and uncorrected valvular heart disease (severe regurgitation or severe stenosis or valvular disease requiring surgery), congenital heart disease, primary pulmonary hypertension or secondary severe pulmonary hypertension (≥ 70 mmHg); large pericardial or pleural effusions; right heart failure due to lung disease; * Recent admission (1 month) for acute decompensated HF; * Angina pectoris, cerebrovascular accident, myocardial infarction, revascularization (PCI or other surgery), carotid artery or other large vessel surgery, or cardiac resynchronization therapy (CRT) implant within the past 3 months; * Planned revascularization within 6 months; * History of heart transplantation, use of ventricular assist device (VAD) or preparation for heart transplantation, VAD; * Liver dysfunction (bilirubin or alkaline phosphatase \> 2 times the upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase \> 3 times the upper limit of normal), estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study (MDRD) method \< 30 ml/min/1.73 m2; * Systolic blood pressure \< 90 mmHg or \> 160 mmHg; * Blood K+ \< 3.2 mmol/L or \> 5.5 mmol/L; * Women of childbearing age who are planning to become pregnant within 2 years, and pregnant or lactating women; * Patients whose survival time is expected to be less than 6 months as judged by the investigator; * Those who have participated in any drug clinical trial within the previous 3 months; * Severe neurological disorders (Alzheimer's disease, progressive parkinsonism); * The subjects with a history of cancer that limits life expectancy to \<1 year; * Endocrine disorders include thyroid disease, thyroid replacement therapy, pheochromocytoma, thyromegaly, etc. * The subject, in the judgment of the Investigator, is unable to complete the study or to comply with the requirements of the study (for administrative or other reasons); * Prisoners; * Adults unable to consent;

Inclusion Criteria

Exclusion Criteria

* Aged 18-80 years, male or female;
* Confirmed diagnosis of ischemic HF with left ventricular ejection fraction (LVEF) ≤ 40% (measured by echocardiography within 1 month of Screening);
* Stable symptoms; NYHA class II-III without recent admission (1 month) for acute decompensation;
* Receiving guideline-based standard HF therapies at the maximum tolerated doses for \>1 month. Patients on other beta-blockers will be switched to metoprolol succinate at equivalent doses for 3 weeks.
* Presence of ICD for \>1 month or implantable cardiac resynchronization therapy defibrillator (CRT-D) for \>3 months
* Understand and sign the informed consent form.

* LVEF \> 40%;
* Unremitting atrial fibrillation during the screening period or clinically significant ventricular tachycardia (on ICD interrogation);
* Non-ischemic HF including hypertrophic cardiomyopathy, peripartum or chemotherapy-induced cardiomyopathy, other non-ischemic cardiomyopathies, constrictive pericarditis, significant and uncorrected valvular heart disease (severe regurgitation or severe stenosis or valvular disease requiring surgery), congenital heart disease, primary pulmonary hypertension or secondary severe pulmonary hypertension (≥ 70 mmHg); large pericardial or pleural effusions; right heart failure due to lung disease;
* Recent admission (1 month) for acute decompensated HF;
* Angina pectoris, cerebrovascular accident, myocardial infarction, revascularization (PCI or other surgery), carotid artery or other large vessel surgery, or cardiac resynchronization therapy (CRT) implant within the past 3 months;
* Planned revascularization within 6 months;
* History of heart transplantation, use of ventricular assist device (VAD) or preparation for heart transplantation, VAD;
* Liver dysfunction (bilirubin or alkaline phosphatase \> 2 times the upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase \> 3 times the upper limit of normal), estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study (MDRD) method \< 30 ml/min/1.73 m2;
* Systolic blood pressure \< 90 mmHg or \> 160 mmHg;
* Blood K+ \< 3.2 mmol/L or \> 5.5 mmol/L;
* Women of childbearing age who are planning to become pregnant within 2 years, and pregnant or lactating women;
* Patients whose survival time is expected to be less than 6 months as judged by the investigator;
* Those who have participated in any drug clinical trial within the previous 3 months;
* Severe neurological disorders (Alzheimer's disease, progressive parkinsonism);
* The subjects with a history of cancer that limits life expectancy to \<1 year;
* Endocrine disorders include thyroid disease, thyroid replacement therapy, pheochromocytoma, thyromegaly, etc.
* The subject, in the judgment of the Investigator, is unable to complete the study or to comply with the requirements of the study (for administrative or other reasons);
* Prisoners;
* Adults unable to consent;

Contacts and Locations

Principal Investigator

Arshed A. Quyyumi, MD

PRINCIPAL_INVESTIGATOR

Emory University

Study Locations (Sites)

Emory University Hospital (EUH)

Atlanta, Georgia, 30322

United States

Emory University Hospital Clinical Research Network

Atlanta, Georgia, 30322

United States

Collaborators and Investigators

Sponsor: Emory University

Arshed A. Quyyumi, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-02

Study Completion Date2026-05

Study Record Updates

Study Start Date2022-12-02

Study Completion Date2026-05

Terms related to this study

Keywords Provided by Researchers

Ischemic Heart Failure
NYHA Class II-III
Implantable Cardioverter Defibrillator (ICD)

Additional Relevant MeSH Terms

Heart Failure